Literature DB >> 9469415

Creating CTL targets with epitope-linked beta 2-microglobulin constructs.

R A Uger1, B H Barber.   

Abstract

Eliciting a strong CTL response is dependent upon displaying suitably high levels of specific class I MHC/peptide complexes at the cell surface. In an effort to enhance the presentation of defined CTL target structures, two unique peptide-linked beta 2-microglobulin (beta 2m) molecules were constructed. The first, designated NP(366-374)-L8-h beta 2m, links the carboxyl terminus of the H-2Db-restricted influenza nucleoprotein (NP) epitope NP(366-374) to the amino terminus of h beta 2m through an eight-amino acid glycine/serine linker. The second molecule, designated NP(147-155)-L12-h beta 2m, similarly couples the H-2Kd-restricted influenza NP epitope NP(147-155) to h beta 2m via a 12-residue polypeptide linker. Transfection of the NP(366-374)-L8-h beta 2m vector into H-2b-expressing cell lines sensitized these cells for lysis by NP(366-374)-specific CTLs. Free NP peptide could not be detected when class I bound peptides were acid-extracted from the surface of NP(366-374)-L8-h beta2m transfectants, indicating that CTL killing was mediated by recognition of the peptide linked to h beta 2m and not by a degradation by-product. CTL target structure formation was also achieved by an exogenous presentation pathway. H-2d-expressing target cells were sensitized for lysis when pulsed with NP(147-155)-L12-h beta 2m protein derived from an Escherichia coli cell lysate. The effect of recombinant NP(147-155)-L12-h beta 2m was inhibited by competitor wild-type h beta 2m, indicating that the active peptide-h beta 2m fusion protein remained intact. The observation that beta 2m with covalently attached peptide can effectively create CTL target structures in vitro offers new possibilities for the in vivo induction of epitope-specific CTL responses by either DNA immunization or injection of the purified epitope-linked beta 2m.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9469415

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  8 in total

Review 1.  Properties and applications of single-chain major histocompatibility complex class I molecules.

Authors:  Eleni Kotsiou; Joanna Brzostek; Keith G Gould
Journal:  Antioxid Redox Signal       Date:  2011-03-31       Impact factor: 8.401

Review 2.  T cell antigen discovery.

Authors:  Alok V Joglekar; Guideng Li
Journal:  Nat Methods       Date:  2020-07-06       Impact factor: 28.547

3.  An efficient and versatile mammalian viral vector system for major histocompatibility complex class I/peptide complexes.

Authors:  Ai Kawana-Tachikawa; Mariko Tomizawa; Jun-Ichi Nunoya; Tatsuo Shioda; Atsushi Kato; Emi E Nakayama; Tetsuya Nakamura; Yoshiyuki Nagai; Aikichi Iwamoto
Journal:  J Virol       Date:  2002-12       Impact factor: 5.103

4.  Cancer immunotherapy using a DNA vaccine encoding a single-chain trimer of MHC class I linked to an HPV-16 E6 immunodominant CTL epitope.

Authors:  C-H Huang; S Peng; L He; Y-C Tsai; D A K Boyd; T H Hansen; T-C Wu; C-F Hung
Journal:  Gene Ther       Date:  2005-08       Impact factor: 5.250

Review 5.  Basic and translational applications of engineered MHC class I proteins.

Authors:  Ted H Hansen; Janet M Connolly; Keith G Gould; Daved H Fremont
Journal:  Trends Immunol       Date:  2010-09-09       Impact factor: 16.687

6.  Antigen-activated dendritic cells ameliorate influenza A infections.

Authors:  Kobporn Boonnak; Leatrice Vogel; Marlene Orandle; Daniel Zimmerman; Eyal Talor; Kanta Subbarao
Journal:  J Clin Invest       Date:  2013-06-24       Impact factor: 14.808

7.  Mimotopes for alloreactive and conventional T cells in a peptide-MHC display library.

Authors:  Frances Crawford; Eric Huseby; Janice White; Philippa Marrack; John W Kappler
Journal:  PLoS Biol       Date:  2004-04-13       Impact factor: 8.029

8.  Immunogenicity of two FMDV nonameric peptides encapsulated in liposomes in mice and the protective efficacy in guinea pigs.

Authors:  Feng-Shan Gao; Lei Feng; Qiang Zhang; Ruo-qian Yan; Yun-Gang Li; Xin-sheng Li
Journal:  PLoS One       Date:  2013-07-09       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.